Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes

XUAN Ji-ming; CHENG Yu-song; GAO Jing; ZHONG Yan-qiang

doi:10.3969/j.issn.1006-0111.2012.01.004

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 30 Issue 1

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2012 > 30(1): 14-18,37

XUAN Ji-ming, CHENG Yu-song, GAO Jing, ZHONG Yan-qiang. Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004

Citation:

XUAN Ji-ming, CHENG Yu-song, GAO Jing, ZHONG Yan-qiang. Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004

Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes

doi: 10.3969/j.issn.1006-0111.2012.01.004

1.
Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Drugs and Instruments Supplying station in Nanjing,Department of health of Jiont logistics of Nanjing Military Region,Shanghai 200052,China

Received Date: 2011-05-22
Rev Recd Date: 2011-12-15

Abstract

Peptide analog of hypoglycemic drugs had a normal physiological function of insulin secretion. The hypoglycemic effect of peptide depended on blood glucose levels of patients, which induced very few incidents of hypoglycemia. Peptides of sustained and controlled release delivery systems in diabetes treatment were summed up in this paper.
- diabetes treatment,
- peptide,
- sustained and controlled release delivery systems

References

[1]	Mei LT, Choong PFM, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery[J]. Peptides, 2010, 31(1):184.
[2]	Park W, Na K. Polyelectrolyte complex of chondroitin sulfate and peptide with lower pI value in poly(lactide-co-glycolide) microsphere for stability and controlled release[J]. Colloids Surf. B Biointerfaces , 2009, 72 (2):193.
[3]	Duchêne D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems[J]. J Control Release, 1999, 62(1-2):263.
[4]	Challa R, Abuja A, Ali J, et al. Cyclodextrins in drug delivery: an updated review[J]. AAPS Pharmscitech, 2005, 6(2):E329.
[5]	Ungaro F, Villa Bianca R, Giovino C, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs[J]. J Control Release, 2009, 135(1):25.
[6]	Agüeros M, Areses P, Campanero MA, et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles[J]. Eur J Pharm. Sci, 2009, 37(3-4):231.
[7]	Agüeros M, Zabaleta V, Espuelas S, et al. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles[J]. J Control Release, 2010, 145(1):2.
[8]	Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery[J]. Int J Pharm, 2006, 325(1-2):147.
[9]	Han YD, Tian HY, He P, et al. Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system[J]. Int J Pharm, 2009, 378(1-2):159.
[10]	Builders PF, Kunle OO, Okpaku LC, et al. Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin[J]. Eur J Pharm Biopharm, 2008, 70(3):777.
[11]	Zhang YL, Wei W, Lv PP, et al. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin[J]. Eur J Pharm Biopharm, 2011, 77(1):11.
[12]	Sonia TA, Sharma CP. In vitro evaluation of N-(2-hydroxy) propyl-3-trimethyl ammonium chitosan for oral insulin delivery[J]. Carbohydrate Polymers, 2011, 84(1):103.
[13]	Pan Y, Xu H, Zhao HY, et al. Study on preparation and oral efficacy of insulin-loaded poly ( lactic-co-glycolic acid)nanoparticles[J] . Acta Pharm Sin (药学学报), 2002, 37(7):374.
[14]	Marco W, Wim EH , Wim J . Protein instability in poly(lactic2co2glycolic acid) nanoparticles[J]. Pharm Res, 2000, 17 (10) :1159.
[15]	Lehr CM, Bouwstra JA , Kok W, et al. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat[J]. J Pharm Pharmacol, 1992, 44(2):402.
[16]	Pimienta C, Chouinard F, Labib A, et al. Effects of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow[J]. Int J Pharm, 1992, 80(1):1.
[17]	Pan Y, Zhao HY, Xu H, et al. Effect of experimental parameters on the encapsulation of insulin-loaded poly(lactide2co2glycolide) nanoparticles prepared by a double emulsion method[J]. J Chin Pharm Sci, 2002, 11(1):38.
[18]	Lee VH.Peptidase activities in absorptive mucosae[J].Biochem Soc, 1989, 17(3):937.
[19]	Jain AK, Chalasani KB, Khar RK, et al. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery[J]. J Drug Target, 2007, 15(6):417.
[20]	杨天智, 王向涛, 阎雪莹, 等. 胰岛素柔性纳米脂质体的口腔给药研究[J]. 药学学报,2002, 37(11):885.
[21]	YIN DF, LU Y, ZHANG H, et al. Preparation of Glucagon-Like Peptide-1 Loaded PLGA Microspheres: Characterizations, Release Studies and Bioactivities in Vitro/in Vivo[J]. Chem Pharm Bull, 2008, 56(2):156.
[22]	Joseph J W, Kalitsky J, St-Pierre S, et al. Oral delivery of glucagon-like peptide-1 in modified polymer preparation normalizes basal glycaemia in diabetic bd/bd mice[J]. Diabetologia, 2000, 43(10):1319.
[23]	Gao ZH, Tang Y, Chen JQ, et al. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres[J]. Peptides, 2009, 30(10):1874.
[24]	Sten Madsbad, Professor. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23(4):463.
[25]	Yang HJ, Park IS, Na K. Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in-water (W1/O/W2) double-emulsion method for delivery of type II diabetic drug (exenatide)[J]. Colloids and Surfaces A: Physicochem Eng Aspects, 2009, 340(1-3):115.
[26]	Nguyen HN, Wey SP, Juang JH, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo[J]. Biomaterials, 2011, 32(10):2673.
[27]	Hanato J, Kuriyama K,et al. Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect[J]. Int J Pharm, 2009, 382(1-2):111.
[28]	Singh M, Shirley B, Bajwa K, et al. Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles[J]. J Control Release, 2001, 70(1-2):21.
[29]	Chen FM, Zhao YM, Wu H, et al. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran-co-gelatin microspheres[J]. J Control Release, 2006, 114(2):209.
[30]	Champa Jayasuriya A.Kibbe S. Rapid biomineralization of chitosan microparticles to apply in bone regeneration[J]. J Mater Sci: Mater Med, 2010, 21(2):393.

Proportional views

通讯作者: 陈斌, [email protected]

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(4686) PDF downloads(398) Cited by()

Proportional views

Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes

1. Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Drugs and Instruments Supplying station in Nanjing,Department of health of Jiont logistics of Nanjing Military Region,Shanghai 200052,China

Received Date: 2011-05-22

Rev Recd Date: 2011-12-15

Key words:

diabetes treatment /
peptide /
sustained and controlled release delivery systems

Abstract: Peptide analog of hypoglycemic drugs had a normal physiological function of insulin secretion. The hypoglycemic effect of peptide depended on blood glucose levels of patients, which induced very few incidents of hypoglycemia. Peptides of sustained and controlled release delivery systems in diabetes treatment were summed up in this paper.

HTML

Reference (30)

[1]	Mei LT, Choong PFM, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery[J]. Peptides, 2010, 31(1):184.
[2]	Park W, Na K. Polyelectrolyte complex of chondroitin sulfate and peptide with lower pI value in poly(lactide-co-glycolide) microsphere for stability and controlled release[J]. Colloids Surf. B Biointerfaces , 2009, 72 (2):193.
[3]	Duchêne D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems[J]. J Control Release, 1999, 62(1-2):263.
[4]	Challa R, Abuja A, Ali J, et al. Cyclodextrins in drug delivery: an updated review[J]. AAPS Pharmscitech, 2005, 6(2):E329.
[5]	Ungaro F, Villa Bianca R, Giovino C, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs[J]. J Control Release, 2009, 135(1):25.
[6]	Agüeros M, Areses P, Campanero MA, et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles[J]. Eur J Pharm. Sci, 2009, 37(3-4):231.
[7]	Agüeros M, Zabaleta V, Espuelas S, et al. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles[J]. J Control Release, 2010, 145(1):2.
[8]	Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery[J]. Int J Pharm, 2006, 325(1-2):147.
[9]	Han YD, Tian HY, He P, et al. Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system[J]. Int J Pharm, 2009, 378(1-2):159.
[10]	Builders PF, Kunle OO, Okpaku LC, et al. Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin[J]. Eur J Pharm Biopharm, 2008, 70(3):777.
[11]	Zhang YL, Wei W, Lv PP, et al. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin[J]. Eur J Pharm Biopharm, 2011, 77(1):11.
[12]	Sonia TA, Sharma CP. In vitro evaluation of N-(2-hydroxy) propyl-3-trimethyl ammonium chitosan for oral insulin delivery[J]. Carbohydrate Polymers, 2011, 84(1):103.
[13]	Pan Y, Xu H, Zhao HY, et al. Study on preparation and oral efficacy of insulin-loaded poly ( lactic-co-glycolic acid)nanoparticles[J] . Acta Pharm Sin (药学学报), 2002, 37(7):374.
[14]	Marco W, Wim EH , Wim J . Protein instability in poly(lactic2co2glycolic acid) nanoparticles[J]. Pharm Res, 2000, 17 (10) :1159.
[15]	Lehr CM, Bouwstra JA , Kok W, et al. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat[J]. J Pharm Pharmacol, 1992, 44(2):402.
[16]	Pimienta C, Chouinard F, Labib A, et al. Effects of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow[J]. Int J Pharm, 1992, 80(1):1.
[17]	Pan Y, Zhao HY, Xu H, et al. Effect of experimental parameters on the encapsulation of insulin-loaded poly(lactide2co2glycolide) nanoparticles prepared by a double emulsion method[J]. J Chin Pharm Sci, 2002, 11(1):38.
[18]	Lee VH.Peptidase activities in absorptive mucosae[J].Biochem Soc, 1989, 17(3):937.
[19]	Jain AK, Chalasani KB, Khar RK, et al. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery[J]. J Drug Target, 2007, 15(6):417.
[20]	杨天智, 王向涛, 阎雪莹, 等. 胰岛素柔性纳米脂质体的口腔给药研究[J]. 药学学报,2002, 37(11):885.
[21]	YIN DF, LU Y, ZHANG H, et al. Preparation of Glucagon-Like Peptide-1 Loaded PLGA Microspheres: Characterizations, Release Studies and Bioactivities in Vitro/in Vivo[J]. Chem Pharm Bull, 2008, 56(2):156.
[22]	Joseph J W, Kalitsky J, St-Pierre S, et al. Oral delivery of glucagon-like peptide-1 in modified polymer preparation normalizes basal glycaemia in diabetic bd/bd mice[J]. Diabetologia, 2000, 43(10):1319.
[23]	Gao ZH, Tang Y, Chen JQ, et al. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres[J]. Peptides, 2009, 30(10):1874.
[24]	Sten Madsbad, Professor. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23(4):463.
[25]	Yang HJ, Park IS, Na K. Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in-water (W1/O/W2) double-emulsion method for delivery of type II diabetic drug (exenatide)[J]. Colloids and Surfaces A: Physicochem Eng Aspects, 2009, 340(1-3):115.
[26]	Nguyen HN, Wey SP, Juang JH, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo[J]. Biomaterials, 2011, 32(10):2673.
[27]	Hanato J, Kuriyama K,et al. Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect[J]. Int J Pharm, 2009, 382(1-2):111.
[28]	Singh M, Shirley B, Bajwa K, et al. Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles[J]. J Control Release, 2001, 70(1-2):21.
[29]	Chen FM, Zhao YM, Wu H, et al. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran-co-gelatin microspheres[J]. J Control Release, 2006, 114(2):209.
[30]	Champa Jayasuriya A.Kibbe S. Rapid biomineralization of chitosan microparticles to apply in bone regeneration[J]. J Mater Sci: Mater Med, 2010, 21(2):393.

Message Board

Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes

doi: 10.3969/j.issn.1006-0111.2012.01.004

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views